MEAD方案治疗复发难治性非霍奇金淋巴瘤20例

The Clinical Efficacy of MEAD Regimen for the Treatment on Recurrent and Refractory Non Hodgkin' s Lymphoma

目的:评价MEAD(MIT,VP16,Ara-C,DXM)方案治疗复发及难治性非霍奇金淋巴瘤近期疗效及毒副反应。方法:20例复发难治性非霍奇金淋巴瘤患者行MEAD方案化疗二周期,MIT 5mg/m2/d,iv gtt,d1-2;Ara—C 60mg/m2/d,iv gtt,d1-5;VP16 80mg/m2/d,iv gtt,d1-5;DXM 10mg,im,d1-5。每4周重复。结果:CR 5例,PR 9例,SD 4例,PD 2例,有效率(CR+PR)70％,毒副反应主要为骨髓抑制。Ⅲ度以上白细胞减少40％,血小板减少15％。经G—CSF或GM—CSF支持后恢复正常。结论:MEAD方案治疗复发难治性非霍奇金淋巴瘤疗效肯定,毒副反应可以耐受。

Objective: To evaluate the antitumor effects and toxicities of MEAD regimen based on mitoxantrone, etoposide, cytarabine and dexamethasonem in the patients with recurrent and refractory non-Hodgkin's lymphoma. Methods: Total of 20 patients were treated with mitoxantrone (5mg/m2 /d given intravenously on day 1-2) ; etoposide (80mg/m2/d given intravenously on day d1-5) , cytarabine (60mg/m2/d given intravenously on d1-5) and dexamethasonum ( 10mg/d given intramuscularly on d1-5). This regimen was repeated every 4 weeks and every patient had gotten 2 cycles treatment. Results: A total of 70% therapeutic response was obtained (25% with CR). Grade III/IV neutropenia was reported in 40% of the patients and Grade III/IV thrombocytopenia in 15% of patients. All of them got G-CSF or GM-CSF treatment and the counts of white blood cells and thrombocytes became normal. Conclusions: MEAD regimen has a good antilymphoma activity, mild toxicity when it was used to treat recurrent and refractory Non-Hodgkin's lymphoma.